TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05997082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Self-Compassion Course
Description: This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).
Study: NCT06626516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp-Tebn
Description: Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tebentafusp-Tebn
Description: Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tebentafusp-Tebn
Description: Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tebentafusp-Tebn
Description: Dosing: All patients enrolled in this study will receive treatment with tebentafusp-tebn based on the approved step-up dosing regimen of 20 mcg on C1D1, 30 mcg on C1D8, then 68 mcg weekly beginning on C1D15 and thereafter. This escalated dose administered at C1D15 will be the dose used for the remainder of the treatment period unless dose reduction is implemented for toxicity. Beginning with C1D8, tebentafusp-tebn will be administered on the scheduled day (± 2 days), and consecutive infusions of tebentafusp-tebn must be administered at least 5 days apart.
Study: NCT05075460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tucidinostat, Azacitidine combined with CHOP
Description: Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat, Azacitidine combined with CHOP
Description: Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment
Study: NCT05282108

Intervention type: DRUG
Intervention: Carcemia
Description: Generic Imatinib
Study: NCT05749029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Week Self-Compassion Course
Description: This is a four-week self-compassion course supplied by Balanced Minds. The owner of Balanced Minds is a Consultant to this study, who will be providing access to participants.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~1. The Foundations of Self-Compassion~2. Developing your Compassionate Self~3. Deepening the Compassionate Relationship with Yourself~4. Self-compassion in Everyday Life.
Study: NCT05282108

Intervention type: DRUG
Intervention: Glivec
Description: Imatinib
Study: NCT06535165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Beetroot Juice
Description: 200ml/d for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200ml/d for 14 days
Study: NCT05976243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib treated groups and arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib treated groups and arms
Study: NCT06626516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF (Sargramostim)
Description: Recombinant human GM-CSF (Sargramostim, Leukine®, Sanofi US) 1,500mg will be mixed with ethiodized oil (Ethiodol®). The GM-CSF/ethiodized oil mixture will be injected selectively into one of the hepatic lobes, followed by infusion of gelatin sponge particles to achieve the stasis of blood flow. This will repeat every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU
Description: Patients will be treated with hepatic artery infusion of 300mg BCNU (1,3-bis \[2-chloroethyl\]-1-nitrosourea, Carmustine) dissolved in ethiodized oil followed by embolization with gelatin sponge particles \[TACE with BCNU 300mg\]; every 4 weeks +/- 7 days in the case of either bilobar or unilobar metastasis
Study: NCT05976243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib treated groups and arms
Study: NCT06625437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
Study: NCT05493657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin single antiplatelet therapy
Description: Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Study: NCT05331651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium in Combination With Tropisetron
Description: Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline in Combination With Tropisetron
Description: Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
Study: NCT05493657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel single antiplatelet therapy
Description: Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Study: NCT05967169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Septal Strap implantation
Description: Correction of NSD with Nasal Septal Strap implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Septal Strap implantation
Description: Correction of NSD with Nasal Septal Strap implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Septal Strap implantation
Description: Correction of NSD with Nasal Septal Strap implant
Study: NCT06700980

Intervention type: OTHER
Intervention: Focus Group
Description: Dutch-speaking patients, Dutch- and/or French-speaking general practitioners and Dutch- and/or French-speaking representatives from pertinent organizational and policy sectors will be questioned in heterogeneous focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
Study: NCT06704867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: Subjects undergoing endoscopic ultrasound will receive high flow nasal cannula during the procedure
Study: NCT06748638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: At 20:00 the night before the examination, pour 2 boxes of lactilose into a cup, add 1000ml of water and drink it; 4 to 6 hours before the examination, dissolve the third box of lactulose into 1000ml water, and drink it; Until pale yellow or clear dung water is drawn.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose+ linaclotide
Description: 1 capsule of linalotide (290ug) taken orally half an hour before meal at 12:00 noon on the previous day， and two doses were taken after 20:00 according to the above Lactulose-taking method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG)
Description: a bag of PEG was dissolved into 1L at 20:00 1d before the examination, and was drunk at a constant rate within 2h; 4 to 6 hours before the inspection, dissolve the second bag of PEG into 2L water and drink it.
Study: NCT06750510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally Delivered Parent Training
Description: The intervention is a universal, digitally delivered parenting program, including 5 themes with recommended length of 1 week each. The total length of the intervention is 8 weeks. The program focuses on positive parenting, encouraging to develop parenting skills that strengthen their relationships and communication with their children.
Study: NCT06751121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 40mg
Description: DWP14012 40 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202301 30mg
Description: DWC202301 30 mg, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 1000mg
Description: Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000mg
Description: Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202301 30mg placebo
Description: DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 40mg placebo
Description: DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
Study: NCT06751134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Description: OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Study: NCT06750926

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: video image through laryngeal mask specific channel
Description: patients placed SaCoVLM will be checked the proper position of placement by native camera through specific video channel and fiberoptic endoscopy through ventilation channel perspectively
Study: NCT06749769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: simulation-based education
Description: Patients will learn how to care for their stomata on a stoma simulator
Study: NCT06750458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin placebo
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dapagliflozin 10 mg once daily for 14 days pre-operative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive placebo tablets once daily for 14 days pre-operative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DexamethasoneGroup III (n=25) (Dexamethasone group)
Description: Twenty-five non-diabetic glioma patients on levetiracetam, and not on SGLT2 inhibitors will receive Dexamethasone 8 mg tablets once daily for 14 days pre-operative.
Study: NCT06748352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FASTER-assisted ESD
Description: The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Description: The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
Study: NCT06749470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jieyu Chufan Capsules
Description: 4 capsules, tid; 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jieyu Chufan Capsules simulant
Description: 4 capsules, tid; 8 weeks
Study: NCT06750809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm Biosynthetic Wound Matrix
Description: Study participants randomized (1:1) to this arm will receive PermeaDerm Biosynthetic Wound Matrix prior to skin graft.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frozen Human Cadaveric Allograft (FHCA)
Description: Study participant randomized (1:1) to this arm will receive Frozen Human Cadaveric Allograft (FHCA) prior to skin graft.
Study: NCT06750198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip focused
Description: Group A will be treated with hip focused exercises and standard rehabilitation protocol.~Hip focused exercises will be comprised of following exercises in phase 1 will be Side lying hip abduction, Hip abduction in standing, Hip extension from prone, Single leg bridge, Side lying clam with resistance while exercises in phase 2 will be same with more repetitions in addition to Side lunges, Forward lunges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehabilitation
Description: Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
Study: NCT06000683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to financial navigation resources
Description: Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reminders
Description: Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Reminers
Description: Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
Study: NCT06748625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Luci Coach-Assisted Intervention
Description: The Luci intervention is a personalized behaviour change program delivered via an interactive web platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement. Participants will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining SMART goals to progressively adopt and maintain a healthier lifestyle. Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
Study: NCT06749873

Intervention type: OTHER
Intervention: Background of different SP information
Description: Sp was asked with the following baseline information: 1. 50 years of age and gender; 2. positive urea breath test; 3. asymptomatic; 4. family history of gastric cancer; 5. gastroscopy: atrophic gastritis; 6. untreated; and 7. no history of drug allergies.
Study: NCT06749119

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft operation
Description: Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft operation
Description: Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .
Study: NCT06748456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast
Description: A pre-recorded podcast with a urologist and a GP discussing the theme to promote preparatory reflections among the GPs before the cluster meeting
Study: NCT05373277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo twice daily for two days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Intervention Description: 90 mg tablet twice daily for two days
Study: NCT06276699

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 1.Isometric exercise 2.combined conservative treatment
Description: Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1.Isometric exercise 2.combined conservative treatment
Description: Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.